3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Acrocephalosyndactylia
5
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Carcinoma, Transitional Cell
3
Recurrence
2
Urinary Bladder Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Myeloproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Eosinophilia
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
8
Specimen Handling
7
Biopsy
6
X-Rays
5
Phantoms, Imaging
5
Temozolomide
4
Nuclear Medicine Department, Hospital
4
Nivolumab
4
Carboplatin
4
selpercatinib
3
larotrectinib
3
Topotecan
3
Etoposide
3
Cyclophosphamide
3
Cisplatin
3
Automobiles
3
tazemetostat
2
pembrolizumab
2
erdafitinib
2
entrectinib
2
ensartinib
2
cabozantinib
2
Vincristine
2
Surveys and Questionnaires
2
Radiotherapy
2
Radiosurgery
2
Radiation
2
Positron-Emission Tomography
2
Paclitaxel
2
ONC206
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
pemigatinib
×
1 year
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts